Medical Surveillance Monthly Report (MSMR). Volume 19, Number 3, March 2012
Abstract
After a 12-year hiatus, military recruit training centers resumed administration of adenovirus type 4 and type 7 vaccine, live, oral (adenovirus vaccine) to trainees beginning in October of 2011. Subsequently, rates of febrile respiratory illnesses (FRI) and adenovirus isolations markedly declined. These findings are consistent with those of a placebo-controlled efficacy trial conducted prior to the vaccine s licensure by the U.S. Food and Drug Administration. Continued surveillance will clarify the longer term impact of vaccine use.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2012
- Accession Number
- ADA558397
Entities
Organizations
- Armed Forces Health Surveillance Center